Business
Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)
Collaboration aims to accelerate candidate development and animal model testing of HaloVax Self-Assembling Vaccine to fight Coronavirus COVID-19 NEW YORK,
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Collaboration aims to accelerate candidate development and animal model testing of HaloVax Self-Assembling Vaccine to fight Coronavirus COVID-19\n\n\nNEW YORK, April 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH). The goal of this partnership is to co-develop a new vaccine designed to protect patients at risk of novel coronavirus (COVID-19) infection, leveraging the Self-Assembling Vaccine (SAV) platform developed by the VIC and licensed exclusively to Voltron Therapeutics, Inc. Voltron will spearhead the development along with its joint development partner Hoth. \n\n \n \n \n \n \n \n\n \nThe vaccine is expected to enter animal testing within the next 30 days. The rapid advancement of this collaboration highlights the partnership between HaloVax and Hoth Therapeutics, to advance this application of VaxCelerate, the SAV platform licensed from the VIC at MGH for vaccine development. \nDr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, MGH stated, \"The self-assembling vaccine has been designed to be highly adaptable, allowing for seamless modifications in the face of potential genetic drifts or future coronaviruses.\"\nPursuant to an agreement announced on March 23, 2020, Hoth shall be granted the right to receive single digit royalties from the sale of any products developed, and shall have the right to acquire up to a 30% equity interest in HaloVax, HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc.\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immu...